The multiple origins of Type 1 diabetes

Diabetic Medicine

Volumn 30, Issue 2, 2013, Pages 135-146

  Pugliese, A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; HLA DRB1 ANTIGEN; INSULIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; STAT5A PROTEIN; T LYMPHOCYTE RECEPTOR;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DIET; DISEASE COURSE; ENVIRONMENTAL FACTOR; GENETIC VARIABILITY; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INTESTINE FLORA; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

AUTOANTIGENS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; DIET; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERGLYCEMIA; INSULIN-SECRETING CELLS; INTESTINES; MALE; METAGENOME; PREDIABETIC STATE; RISK FACTORS;

EID: 84872716878     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12081     Document Type: Review

References (125)

1. Vehik K, Beam CA, Mahon JL, Schatz DA, Haller MJ, Sosenko JM et al. Development of autoantibodies in the TrialNet Natural History Study. Diabetes Care 2011; 34: 1897-1901.
2. Roep BO, Peakman M. Diabetogenic T lymphocytes in human Type 1 diabetes. Curr Opin Immunol 2011; 23: 746-753.
3. Pociot F, Akolkar B, Concannon P, Erlich HA, Julier C, Morahan G et al. Genetics of Type 1 diabetes: what's next? Diabetes 2010; 59: 1561-1571.
4. Barker JM, Barriga KJ, Yu L, Miao D, Erlich HA, Norris JM et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004; 89: 3896-3902.
5. Derbinski J, Kyewski B. How thymic antigen presenting cells sample the body's self-antigens. Curr Opin Immunol 2010; 22: 592-600.
6. Fan Y, Rudert WA, Grupillo M, He J, Sisino G, Trucco M. Thymus-specific deletion of insulin induces autoimmune diabetes. EMBO J 2009; 28: 2812-2824.
7. Pugliese A, Zeller M, Fernandez AJ, Zalcberg LJ, Bartlett RJ, Ricordi C et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997; 15: 293-297.
8. Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyear CG et al. Insulin expression in the thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 1997; 15: 289-292.
9. Diez J, Park Y, Zeller M, Brown D, Garza D, Ricordi C et al. Differential splicing of the IA-2 mRNA in pancreas and lymphoid organs as a permissive genetic mechanism for autoimmunity against the IA-2 type 1 diabetes autoantigen. Diabetes 2001; 50: 895-900.
10. Dogra RS, Vaidyanathan P, Prabakar KR, Marshall KE, Hutton JC, Pugliese A. Alternative splicing of G6PC2, the gene coding for the islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), results in differential expression in human thymus and spleen compared with pancreas. Diabetologia 2006; 49: 953-957.
11. Durinovic-Bello I, Wu RP, Gersuk VH, Sanda S, Shilling HG, Nepom GT. Insulin gene VNTR genotype associates with frequency and phenotype of the autoimmune response to proinsulin. Genes Immun 2010; 11: 188-193.
12. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002; 298: 1395-1401.
13. Sabater L, Ferrer-Francesch X, Sospedra M, Caro P, Juan M, Pujol-Borrell R. Insulin alleles and autoimmune regulator (AIRE) gene expression both influence insulin expression in the thymus. J Autoimmun 2005; 25: 312-318.
14. Noso S, Kataoka K, Kawabata Y, Babaya N, Hiromine Y, Yamaji K et al. Insulin transactivator MafA regulates intrathymic expression of insulin and affects susceptibility to type 1 diabetes. Diabetes 2010; 59: 2579-2587.
15. Pugliese A, Brown D, Garza D, Murchison D, Zeller M, Redondo M et al. Self-antigen-presenting cells expressing diabetes-associated autoantigens exist in both thymus and peripheral lymphoid organs. J Clin Invest 2001; 107: 555-564.
16. Zhu M, Chin RK, Christiansen PA, Lo JC, Liu X, Ware C et al. NF-κB2 is required for the establishment of central tolerance through an Aire-dependent pathway. J Clin Invest 2006; 116: 2964-2971.
17. Hubert FX, Kinkel SA, Davey GM, Phipson B, Mueller SN, Liston A et al. Aire regulates the transfer of antigen from mTECs to dendritic cells for induction of thymic tolerance. Blood 2011; 118: 2462-2472.
18. Noble JA, Erlich HA. Genetics of type 1 diabetes. Cold Spring Harb Perspect Med 2012; 2: a007732.
19. van Lummel M, van Veelen PA, Zaldumbide A, de Ru A, Janssen GM, Moustakas AK et al. Type 1 diabetes-associated HLA-DQ8 transdimer accommodates a unique peptide repertoire. J Biol Chem 2012; 287: 9514-9524.
20. Hermann R, Knip M, Veijola R, Simell O, Laine AP, Akerblom HK et al. Temporal changes in the frequencies of HLA genotypes in patients with Type 1 diabetes-indication of an increased environmental pressure? Diabetologia 2003; 46: 420-425.
21. Gillespie KM, Bain SC, Barnett AH, Bingley PJ, Christie MR, Gill GV et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 2004; 364: 1699-1700.
22. Fourlanos S, Varney MD, Tait BD, Morahan G, Honeyman MC, Colman PG et al. The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabetes Care 2008; 31: 1546-1549.
23. Vehik K, Hamman RF, Lezotte D, Norris JM, Klingensmith GJ, Rewers M et al. Trends in high-risk HLA susceptibility genes among Colorado youth with type 1 diabetes. Diabetes Care 2008; 31: 1392-1396.
24. Resic-Lindehammer S, Larsson K, Ortqvist E, Carlsson A, Cederwall E, Cilio CM et al. Temporal trends of HLA genotype frequencies of type 1 diabetes patients in Sweden from 1986 to 2005 suggest altered risk. Acta Diabetol 2008; 45: 231-235.
25. Vehik K, Dabelea D. The changing epidemiology of type 1 diabetes: why is it going through the roof? Diabetes Metab Res Rev 2011; 27: 3-13.
26. Bulek AM, Cole DK, Skowera A, Dolton G, Gras S, Madura F et al. Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. Nat Immunol 2012; 13: 283-289.
27. Mohan JF, Petzold SJ, Unanue ER. Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med 2011; 208: 2375-2383.
28. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005; 435: 220-223.
29. Suri A, Walters JJ, Gross ML, Unanue ER. Natural peptides selected by diabetogenic DQ8 and murine I-A(g7) molecules show common sequence specificity. J Clin Invest 2005; 115: 2268-2276.
30. Vang T, Congia M, Macis MD, Musumeci L, Orru V, Zavattari P et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005; 37: 1317-1319.
31. Schubert DA, Gordo S, Sabatino JJ Jr, Vardhana S, Gagnon E, Sethi DK et al. Self-reactive human CD4 T-cell clones form unusual immunological synapses. J Exp Med 2012; 209: 335-352.
32. Yang XY, Levi D, Ounissi-Benkalha H, Yu XY, Qu HQ, Polychronakos C et al. Screening for novel lead compounds increasing insulin expression in medullary thymic epithelial cells. Eur J Pharmacol 2012; 688: 84-89.
33. Michels AW, Ostrov DA, Zhang L, Nakayama M, Fuse M, McDaniel K et al. Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. J Immunol 2011; 187: 5921-5930.
34. Tsai S, Shameli A, Yamanouchi J, Clemente-Casares X, Wang J, Serra P et al. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 2010; 32: 568-580.
35. Liu Z, Cort L, Eberwine R, Herrmann T, Leif JH, Greiner DL et al. Prevention of type 1 diabetes in the rat with an allele-specific anti-T-cell receptor antibody: Vβ13 as a therapeutic target and biomarker. Diabetes 2012; 61: 1160-1168.
36. Poliani PL, Kisand K, Marrella V, Ravanini M, Notarangelo LD, Villa A et al. Human peripheral lymphoid tissues contain autoimmune regulator-expressing dendritic cells. Am J Pathol 2010; 176: 1104-1112.
37. Grupillo M, Gualtierotti G, He J, Sisino G, Bottino R, Rudert WA et al. Essential roles of insulin expression in Aire+ tolerogenic dendritic cells in maintaining peripheral self-tolerance of islet beta-cells. Cell Immunol 2012; 273: 115-123.
38. Gardner JM, DeVoss JJ, Friedman RS, Wong DJ, Tan YX, Zhou X et al. Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 2008; 321: 843-847.
39. Cohen JN, Guidi CJ, Tewalt EF, Qiao H, Rouhani SJ, Ruddell A et al. Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. J Exp Med 2010; 207: 681-688.
40. Fletcher AL, Lukacs-Kornek V, Reynoso ED, Pinner SE, Bellemare-Pelletier A, Curry MS et al. Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. J Exp Med 2010; 207: 689-697.
41. Kodama K, Butte AJ, Creusot RJ, Su L, Sheng D, Hartnett M et al. Tissue- and age-specific changes in gene expression during disease induction and progression in NOD mice. Clin Immunol 2008; 129: 195-201.
42. Yip L, Su L, Sheng D, Chang P, Atkinson M, Czesak M et al. Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. Nat Immunol 2009; 10: 1026-1033.
43. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010; 10: 849-859.
44. Ferraro A, Socci C, Stabilini A, Valle A, Monti P, Piemonti L et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011; 60: 2903-2913.
45. Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, Grabowska M, Techmanska I, Juscinska J et al. Administration of CD4 + CD25highCD127- regulatory T cells preserves beta-cell function in Type 1 diabetes in children. Diabetes Care 2012; 35: 1817-1820.
46. Vang T, Miletic AV, Bottini N, Mustelin T. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity 2007; 40: 453-461.
47. Menard L, Saadoun D, Isnardi I, Ng YS, Meyers G, Massad C et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest 2011; 121: 3635-3644.
48. O'Neill SK, Liu E, Cambier JC. Change you can B(cell)eive in: recent progress confirms a critical role for B cells in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2009; 16: 293-298.
49. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361: 2143-2152.
50. Cox SL, Silveira PA. Emerging roles for B lymphocytes in Type 1 diabetes. Expert Rev Clin Immunol 2009; 5: 311-324.
51. Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007; 39: 1074-1082.
52. Garg G, Tyler JR, Yang JH, Cutler AJ, Downes K, Pekalski M et al. Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4 + CD25 + regulatory T-cell function. J Immunol 2012; 188: 4644-4653.
53. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010; 33: 153-165.
54. Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VE et al. Interleukin-2 gene variation impairs regulatory T-cell function and causes autoimmunity. Nat Genet 2007; 39: 329-337.
55. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008; 28: 687-697.
56. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010; 207: 1871-1878.
57. Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011; 365: 2067-2077.
58. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP III et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365: 2055-2066.
59. Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R et al. Rapamycin/IL-2 combination therapy in patients with Type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 2012; 61: 2340-2348.
60. Mallone R, Scotto M, Janicki CN, James EA, Fitzgerald-Miller L, Wagner R et al. Immunology of Diabetes Society T-Cell Workshop: HLA class I tetramer-directed epitope validation initiative T-Cell Workshop Report-HLA Class I Tetramer Validation Initiative. Diabetes Metab Res Rev 2011; 27: 720-726.
61. Brooks-Worrell B, Gersuk VH, Greenbaum C, Palmer JP. Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. J Immunol 2001; 166: 5265-5270.
62. Mannering SI, Morris JS, Jensen KP, Purcell AW, Honeyman MC, Van Endert PM et al. A sensitive method for detecting proliferation of rare autoantigen-specific human T cells. J Immunol Methods 2003; 283: 173-183.
63. Schloot NC, Meierhoff G, Karlsson FM, Ott P, Putnam A, Lehmann P et al. Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third Immunology of Diabetes Society T-cell workshop. J Autoimmun 2003; 21: 365-376.
64. Mallone R, Martinuzzi E, Blancou P, Novelli G, Afonso G, Dolz M et al. CD8 + T-cell responses identify beta-cell autoimmunity in human type 1 diabetes. Diabetes 2007; 56: 613-621.
65. Nepom GT. MHC multimers: expanding the clinical toolkit. Clin Immunol 2003; 106: 1-4.
66. Velthuis JH, Unger WW, Abreu JR, Duinkerken G, Franken K, Peakman M et al. Simultaneous detection of circulating autoreactive CD8 + T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010; 59: 1721-1730.
67. Kent SC, Chen Y, Bregoli L, Clemmings SM, Kenyon NS, Ricordi C et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 2005; 435: 224-228.
68. Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, Atkinson MA et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 2012; 209: 51-60.
69. Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010; 59: 947-957.
70. Skowera A, Ellis RJ, Varela-Calvino R, Arif S, Huang GC, Van-Krinks C et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008; 118: 3390-3402.
71. Kronenberg D, Knight RR, Estorninho M, Ellis RJ, Kester MG, de Ru A et al. Circulating pre-proinsulin signal peptide-specific CD8 T cells restricted by the susceptibility Molecule HLA-A24 are expanded at onset of Type 1 diabetes and kill beta-cells. Diabetes 2012; 61: 1752-1759.
72. Monti P, Heninger AK, Bonifacio E. Differentiation, expansion, and homeostasis of autoreactive T cells in type 1 diabetes mellitus. Curr Diab Rep 2009; 9: 113-118.
73. Viglietta V, Kent SC, Orban T, Hafler DA. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest 2002; 109: 895-903.
74. Jaeger C, Brendel MD, Eckhard M, Bretzel RG. Islet autoantibodies as potential markers for disease recurrence in clinical islet transplantation. Exp Clin Endocrinol Diabetes 2000; 108: 328-333.
75. Hilbrands R, Huurman VA, Gillard P, Velthuis JH, De WM, Mathieu C et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 2009; 58: 2267-2276.
76. Stene LC, Rewers M. Immunology in the clinic review series; focus on type 1 diabetes and viruses: the enterovirus link to type 1 diabetes: critical review of human studies. Clin Exp Immunol 2012; 168: 12-23.
77. Viskari H, Knip M, Tauriainen S, Huhtala H, Veijola R, Ilonen J et al. Maternal enterovirus infection as a risk factor for type 1 diabetes in the exposed offspring. Diabetes Care 2012; 35: 1328-1332.
78. Jaidane H, Sane F, Hiar R, Goffard A, Gharbi J, Geenen V et al. Immunology in the clinic review series; focus on type 1 diabetes and viruses: enterovirus, thymus and type 1 diabetes pathogenesis. Clin Exp Immunol 2012; 168: 39-46.
79. Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG. The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia 2009; 52: 1143-1151.
80. Foulis AK, Farquharson MA, Meager A. Immunoreactive α-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987; 2: 1423-1427.
81. Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A 2007; 104: 5115-5120.
82. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Immunohistochemical analysis of the relationship between islet cell proliferation and the production of the enteroviral capsid protein, VP1, in the islets of patients with recent-onset type 1 diabetes. Diabetologia 2011; 54: 2417-2420.
83. In't Veld P. Insulitis in the human endocrine pancreas: does a viral infection lead to inflammation and beta cell replication? Diabetologia 2011; 54: 2220-2222.
84. Chapman NM, Kim KS. Persistent coxsackievirus infection: enterovirus persistence in chronic myocarditis and dilated cardiomyopathy. Curr Top Microbiol Immunol 2008; 323: 275-292.
85. Chistiakov DA. Interferon induced with helicase C domain 1 (IFIH1) and virus-induced autoimmunity: a review. Viral Immunol 2010; 23: 3-15.
86. Brooks-Worrell B, Palmer JP. Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin Exp Immunol 2012; 167: 40-46.
87. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005; 48: 2206-2212.
88. Leslie RD, Williams R, Pozzilli P. Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 2006; 91: 1654-1659.
89. Grant SF, Hakonarson H, Schwartz S. Can the genetics of type 1 and type 2 diabetes shed light on the genetics of latent autoimmune diabetes in adults? Endocr Rev 2010; 31: 183-193.
90. Goel A, Chiu H, Felton J, Palmer JP, Brooks-Worrell B. T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe beta-cell lesions in phenotypic type 2 diabetes. Diabetes 2007; 56: 2110-2115.
91. Liu LL, Lawrence JM, Davis C, Liese AD, Pettitt DJ, Pihoker C et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes 2010; 11: 4-11.
92. Pang TT, Narendran P. Addressing insulin resistance in Type 1 diabetes. Diabet Med 2008; 25: 1015-1024.
93. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004; 47: 1661-1667.
94. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004; 53: S16-21.
95. Dabelea D, D'Agostino RB Jr, Mayer-Davis EJ, Pettitt DJ, Imperatore G, Dolan LM et al. Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. Diabetes Care 2006; 29: 290-294.
96. Bingley PJ, Mahon JL, Gale EA. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2008; 31: 146-150.
97. Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes 2010; 59: 679-685.
98. Oresic M, Simell S, Sysi-Aho M, Nanto-Salonen K, Seppanen-Laakso T, Parikka V et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 2008; 205: 2975-2984.
99. Pflueger M, Seppanen-Laakso T, Suortti T, Hyotylainen T, Achenbach P, Bonifacio E et al. Age- and islet autoimmunity-associated differences in amino acid and lipid metabolites in children at risk for type 1 diabetes. Diabetes 2011; 60: 2740-2747.
100. Eizirik DL, Sammeth M, Bouckenooghe T, Bottu G, Sisino G, Igoillo-Esteve M et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet 2012; 8: e1002552.
101. Oikarinen M, Tauriainen S, Oikarinen S, Honkanen T, Collin P, Rantala I et al. Type 1 diabetes is associated with enterovirus infection in gut mucosa. Diabetes 2012; 61: 687-691.
102. Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS ONE 2011; 6: e25792.
103. Sarkar SA, Lee CE, Victorino F, Nguyen TT, Walters JA, Burrack A et al. Expression and regulation of chemokines in murine and human type 1 diabetes. Diabetes 2012; 61: 436-446.
104. Alkanani AK, Rewers M, Dong F, Waugh K, Gottlieb PA, Zipris D. Dysregulated toll-like receptor-induced interleukin-1β and interleukin-6 responses in subjects at risk for the development of Type 1 diabetes. Diabetes 2012; 61: 2525-2533.
105. Mizrahi M, Ilan Y. The gut mucosa as a site for induction of regulatory T-cells. Curr Pharm Des 2009; 15: 1191-1202.
106. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
107. Ablamunits V, Henegariu O, Hansen JB, Opare-Addo L, Preston-Hurlburt P, Santamaria P et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012; 61: 145-154.
108. Hummel S, Ziegler AG. Early determinants of type 1 diabetes: experience from the BABYDIAB and BABYDIET studies. Am J Clin Nutr 2011; 94: 1821S-1823S.
109. Hagopian WA, Erlich H, Lernmark A, Rewers M, Ziegler AG, Simell O et al. The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. Pediatr Diabetes 2011; 12: 733-743.
110. Nelson P, Smith N, Ciupe S, Zou W, Omenn GS, Pietropaolo M. Modeling dynamic changes in type 1 diabetes progression: quantifying beta-cell variation after the appearance of islet-specific autoimmune responses. Math Biosci Eng 2009; 6: 753-778.
111. Coppieters K, Amirian N, von HM. Intravital imaging of CTLs killing islet cells in diabetic mice. J Clin Invest 2012; 122: 119-131.
112. Fousteri G, Jasinski J, Dave A, Nakayama M, Pagni P, Lambolez F et al. Following the fate of one insulin-reactive CD4 T cell: conversion into Teffs and Tregs in the periphery controls diabetes in NOD mice. Diabetes 2012; 61: 1169-1179.
113. Akirav EM, Lebastchi J, Galvan EM, Henegariu O, Akirav M, Ablamunits V et al. Detection of beta cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci U S A 2011; 108: 19018-19023.
114. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006; 29: 643-649.
115. Sosenko JM, Skyler JS, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE et al. Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). Diabetes 2010; 59: 2386-2389.
116. Tsai EB, Sherry NA, Palmer JP, Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 2006; 49: 261-270.
117. Greenbaum CJ, Anderson AM, Dolan LM, Mayer-Davis EJ, Dabelea D, Imperatore G et al. Preservation of beta-cell function in autoantibody-positive youth with diabetes. Diabetes Care 2009; 32: 1839-1844.
118. Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet Data. Diabetes 2012; 61: 2066-2073.
119. Gianani R, Campbell-Thompson M, Sarkar SA, Wasserfall C, Pugliese A, Solis JM et al. Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 2010; 53: 690-698.
120. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 2005; 48: 2221-2228.
121. Keenan HA, Sun JK, Levine J, Doria A, Aiello LP, Eisenbarth G et al. Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010; 59: 2846-2853.
122. Klinke DJ. Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS One 2008; 3: e1374.
123. In't Veld P. Insulitis in human type 1 diabetes: the quest for an elusive lesion. Islets 2011; 3: 131-138.
124. Skyler JS, Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes 2011; 60: 1-8.
125. Campbell-Thompson M, Wasserfall C, Kaddis J, Albanese-O'Neill A, Staeva T, Nierras C et al. Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab Res Rev 2012; 28: 608-617.